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Calcitonin Gene Peptides: The Diagnostic Value of Measurement in 
Medullary Thyroid Carcinoma 
Samia I. Girgis,* Catherine Lynch, Carmel J. Hillyard, John C. Stevenson, Patricia A. 
Hill, David W.R. MacDonald, and Iain Macintyre 
The calcitonin gene encodes a family of peptides, at least three of which normally circulate in man: 
calcitonin (CT), a calcium-lowering hormone; katacalcin (KC), a peptide of unknown function; and 
calcitonin gene-related peptide (CGRP), a neuropeptide and potent vasodilator. In a study of 45 
patients with medullary thyroid carcinoma (MTC), plasma CGRP was elevated in approximately 50% 
of cases. Furthermore, CGRP levels did not correlate with CT levels. However, plasma KC was 
elevated in all cases, with a good correlation with CT levels, as has been noted previously. 
M easurement of CT or KC appears to be superior to measurement of CGRP for the detection of MTC. 
(Henry Ford Hosp MedJ 1987;35:118-9) 
An overview of three products of the human calcitonin gene is presented here with particular reference to the diagnostic 
value of their measurement in medullary thyroid carcinoma (MTC). 
Calcitonin 
The recognition of calcitonin (CT) as a tumor marker for 
MTC was the product of a sequence of exciting contributions 
made by scientists working in various disciplines of medical sci-
ence. Following the discovery of a calcium-lowering factor, 
"calcitonin," by Copp and Cheney (1) who believed CT to be of 
parathyroid origin, further studies demonstrated the thyroid ori-
gin of this factor (2,3). In 1964, Foster et al (4) identified the 
parafollicular cells of the thyroid gland as the source of CT, and 
the term "C-cells" (C for calcitonin) was introduced by Pearse 
(5). Later, Williams suggested that MTC is a tumor of the para-
follicular cells (6). This suggestion proved correct as two impor-
tant developments followed: 1) the isolation and characterization 
of CT from a single MTC tumor (7), and 2) the demonstration of 
high levels of CT (measured in bioassay) in the plasma of pa-
tients with MTC (8,9) in whom calcium (Ca) infusion produced 
a further increase in CT levels. 
The characterization of human CT in 1968 (10) was followed 
in the same year by its synthesis (11). This, together with 
advances in radioimmunoassay (RIA) techniques, has permit-
ted the development of a specific RIA for human CT in various 
laboratories (12,13). 
MTC is now classically diagnosed by the detection of high 
levels of immunoreactive CT in plasma. In patients with C-cell 
hyperplasia in whom basal CT levels are normal, the diagnosis 
can be made by observing an exaggerated response to stimula-
tion of release by either Ca, pentagastrin, or alcohol (13-16), ora 
combination of Ca and pentagastrin. 
Katacalcin or PDN-21 
The complete sequence of the human CT precursor has been 
predicted by cloning and analysis of recombinant DNA from 
messenger RNA extracted from human MTC (17,18). This re-
vealed that CT is flanked on its carboxy-terminus by a 21 amino 
acid peptide and on its amino-terminus by a larger peptide of 
82 amino acids. 
When the carboxy-terminus peptide (PDN-21) was synthe-
sized, it was thought initially to have a Ca-lowering activity; 
hence the introduction of the name katacalcin (KC) (19). How-
ever, it is now clear that KC has no Ca-lowering activity, and its 
function, if any, is not yet known. Using specific RIA, KC is 
shown to circulate at high levels in patients with MTC (19-21) 
and at approximately equimolar amounts with CT, Furthermore, 
KC release responds to the same stimuli as CT (19-21). There-
fore, diagnostically, KC is as good a marker as CT for the detec-
tion of MTC and C-cell hyperplasia. 
Calcitonin Gene-Related Peptide 
The CT gene encodes the precursor of another peptide, cal-
citonin gene-related peptide (CGRP). This peptide was predicted on 
the basis of nucleotide sequence data from the rat (22) and was 
thought to arise from differential tissue-specific processing of the 
transcript from the rat CT gene. Its existence in the rat was sug-
gested by immunofluorescent localization (23), and it was shown to 
be widely distributed in the central nervous system. 
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We have isolated and characterized a related peptide from 
human MTC tumor (h-CGRP) (24), CGRP has been shown to be 
the most potent vasodilator yet discovered (25,26). Recently, we 
have shown that immunoreactive CGRP normally circulates in 
humans in higher concentrations than immunoreactive CT (27). 
More recentiy we have studied the circulating levels of CGRP, 
together with CT and KC, in 45 patients with MTC. Plasma 
CGRP was elevated in approximately 50% of cases (Figure). 
There was a weak correlation between CGRP levels and either 
CT or KC levels. However, plasma CT and KC were elevated in 
all cases and circulated in equimolar amounts. Their levels were 
approximately tenfold higher than those of CGRP. We have con-
cluded that CGRP is not a sensitive marker for MTC, and mea-
surement of CT or KC is superior to measurement of CGRP for 
the detection of MTC. 
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